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Results: Of 134 allo-HSCTs, 29 (21.6%) patients experienced
CMV viremia. Among these patients, median age was 51
years (range 27-67), with 48 episodes of viremia. Nine (31%)
viremic patients developed CMV disease.
CMV disease occurred at a median of 124 days post HSCT
(range 61-322). Patients with CMV disease had a median of 2
viremic episodes before disease (range 1-4). Disease
occurred at a median of 33 days from the start of the last
viremic episode, and 75 days from the start of the ﬁrst
episode of viremia.
On univariate analysis, factors associated with progres-
sion to CMV disease were: steroid-refractory acute GVHD (60
vs. 20%, p¼0.028); number of episodes of viremia >1x103
copies/mL (mean 2.4 vs 1.1, p¼0.016); longer duration of
viremia (mean 38 vs. 22 days, p¼0.01); higher peak viral load
(mean 4.49x105 vs. 8.31x103 copies/mL, p<0.001); and fail-
ure of pre-emptive ganciclovir therapy (50 vs. 10%, p¼0.015).
On multivariate analysis, no factors were signiﬁcantly asso-
ciated with progression to CMV disease.
CMV-related mortality was 33%. All-cause mortality was
signiﬁcantly higher in patients developing CMV disease (100
vs. 35%, log rank test p¼0.0027).
Conclusions: In adult allo-HSCT recipients experiencing 1
episode of CMV viremia, we found by univariate analysis that
patients who developed CMV disease were more likely to
have steroid refractory acute GVHD, more episodes of
viremia >1x103 copies/mL, a longer duration of viremia, and
to have failed ﬁrst-line pre-emptive ganciclovir therapy. This
study, while limited, suggests that these risk factors may be
predictive of CMV disease. Larger, prospective studies are
needed to conﬁrm these risk factors, some of which may be
amenable to more aggressive anti-viral therapy.425
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Introduction: Haplo-HCT is used increasingly as a treatment
for patients with hematologic disorders lacking suitable HLA
matched donors. Graft failure or rejection after myelo-
ablative conditioning (MAC) carries high mortality. We
present case of a patient with graft rejection post haplo-HCT
salvaged with second haplo-HCT using second related
donor.
Case Report: A 28 year old male presented with 3 week his-
tory of progressive weakness. He was severely pancytopenic
withWBC of 2.4, Hb of 4g/dl and platelet count of 14k. Work-
up for secondary causes of pancytopenia was negative.
Complete blood count performed a year earlier was normal.
Bone marrow was 70% cellular with dyserythropoiesis,
decreased megakaryocytes and normal myeloid precursors.
Marrow cytogenetics and Fluorescent in-situ Hybridization
panel for myelodysplastic syndrome was normal. Peripheral
blood ﬂow cytometry for paroxysmal nocturnal hemoglo-
binuria showed a small CD59 deﬁcient red cell clone (1.9%).His cytopenias progressed on high dose steroids. Repeat
marrow 4 weeks later was similar to his original marrow.
Patient had no suitable HLA matched related or unrelated
donor. He underwent Tcell replete peripheral blood stem cell
transplantation (PBSCT) from his haplomatched sister
following MAC with ﬂudarabine (FLU), busulfan and cyclo-
phosphamide (CY) with post transplant CY (PTC) and graft
versus host disease (GVHD) prophylaxis withmycophenolate
mofetil (MMF) and tacrolimus. Cell dose was CD34/kg 5 x 106
and CD3/kg 4.76 x 1010. Pretransplant screening for donor
speciﬁc antibodies (DSA) was negative. Four weeks after
transplant, patient remained severely pancytopenic. Bone
marrow exam showed an acellular marrow and peripheral
chimerism studies were fully recipient. Repeat screening for
DSA was again negative. Patient underwent a second T cell
replete PBSCTon day 39 using his haplomatched father as the
donor. The identical haplotype of the father was different
from his original donor. Patient underwent reduced intensity
conditioningwith FLU, CYand TBI 200 cGywith standard PTC
andGVHDprophylaxiswithMMFand tacrolimus. Post second
transplant, patient neutrophil and platelet engrafted on day
19andday32 respectively. Chimerismpost secondhaplo-HCT
was fully donor. During hospital course patient had multiple
complications. He developed fungemia (Debaryomyces spe-
cies) on day 24 postﬁrst transplant. Post second transplant he
developed oliguric renal failure requiring transient hemodi-
alysis and liver function test (LFT) abnormalities with peak
bilirubin of 12.1mg/dl. Liver biopsy showed drug induced
toxicity. Both his renal function and his LFT have since
improved and are near normal.
Conclusion: Graft rejection in a patient undergoing hap-
loidentical transplant could be successfully salvaged with a
second transplant using a different haploidentical donor and
with reduced intensity conditioning.426
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Background: VTE is a potentially life threatening condition
that requires early recognition and treatment. An increased
incidence of VTE with sirolimus-based immunosuppressive
regimen has been reported in solid organ transplant. Limited
data exist on VTE incidence in allo-HCT with sirolimus-based
GVHD prophylaxis.
Materials and Methods: We analyzed 892 consecutive allo-
HCT recipients between 1/1/2008 and 12/31/2013 at Mofﬁtt
Cancer Center. Baseline characteristics and VTE events were
collected. The association between VTE and baseline char-
acteristics including sirolimus and non-sirolimus GVHD
regimen was assessed using the Cox proportional hazard
model. The signiﬁcance level was set at  0.05. All analyses
were performed using Stata statistical analysis software
version 13.
